Figure S1. Comparison of 10 candidate circRNA expression levels between BLD regimen treated patients and BCD regimen treated patients. Expression levels of (A) circ_0026652, (B) circ_0068708, (C) circ_0088128, (D) circ_0001566, (E) circ_0005327, (F) circ_0031113, (G) circ_0083587, (H) circ_0005552, (I) circ_0007171 and (J) circ_0007521 in BLD regimen treated patients and BCD regimen treated patients. BLD, bortezomib/lenalidomide/dexamethasone; BCD, bortezomib/cyclophosphamide/dexamethasone; circRNA/circ, circular RNA.
Figure S2. Time-dependent effect of circ_0026652 knockdown on MM chemosensitivity to bortezomib. (A) Relative cell viability under 4 nM bortezomib treatment at 0, 24, 48 and 72 h in U266 cells. (B) Relative cell viability under 1 nM bortezomib treatment at 0, 24, 48 and 72 h in RPMI-8226 cells. *P<0.05, **P<0.01. circ, circular RNA; MM, multiple myeloma; si, small interfering RNA; NC, negative control.
Figure S3. miR-608 expression after transfection. miR-608 expression among control, NC-inhibitor and miR-inhibitor groups in (A) U266 and (B) RPMI-8226 cells. ***P<0.001. NC, negative control; miR, microRNA.